**Molecular Pathology Request Form**

|  |  |
| --- | --- |
| Please send requests to | **Molecular Neuropathology Laboratory**Division of Neuropathology | UCL Queen Square Institute of Neurology | Queen Square |London WC1N 3BG | email: UCLH.molecular.neuropathology@nhs.net |
| Web address for further information and form download | <https://www.ucl.ac.uk/ion/divisions/neuropathology/diagnostic_services/molecular_tests>**.** **Always print this form and send with the sample. Do not alter this form.** |
| **For Laboratory use only** |  **NH**  |  Time stamp  |   |
| **Test requested** | **Test method: see website** |  |
| **CN**: 1p, 19q, 7p (EGFR), CDKN2A/B**Seq**.: IDH1, IDH2, H3.3 K27M + G34R), TERT, BRAF V600E |[ ]  Suspected Glioblastoma, IDH-wildtype. Not useful for LGG, unusual HGG, paediatric tumours or meningioma | **USS or FFPE block****& Pathology report** |
| **Seq:** IDH1, IDH2, H3.3 K27M + G34R), TERT, BRAF V600E |[ ]  **Low and high-grade astrocytic tumours**:To identify IDH-wildtype GBM in under-sampled biopsies | **USS or FFPE block** **& Pathology report** |
| IHC |[ ]  H3K27M |  | **USS or FFPE block**  |
| EGFR amplification only |[ ]  EGFR amplification | **USS or FFPE block**  |
| EGFR amplification + EGFRvIII |[ ]  vIII mutation will be tested only for EGFR-amplified tumours | **USS or FFPE block** |
| BRAF V600E mutation  |[ ]  Melanoma, LGG  | **USS or FFPE block** |
| MGMT promoter methylation |[ ]  Gliomas undergoing treatment with Temozolomide | **USS or FFPE block**  |
| Illumina 850k methylation array |[ ]  To classify brain tumours (except meningiomas) using the Heidelberg classifier. Recommended for: Astrocytomas, oligodendrogliomas, ependymal tumours, unclear high- and low-grade CNS tumours, all posterior fossa & spinal tumours  | **FFPE block** **& Pathology report** |
| Illumina 850k methylation array, MENINGIOMAS (includes CDKN2A/B) |[ ]  To [classify **Meningiomas**](https://pubmed.ncbi.nlm.nih.gov/34618539/) using the Heidelberg classifier v12.6 |[ ]  TERT prom. mutation | **FFPE block****& Pathology report** |
| [Next Generation Sequencing (NGS)](https://shared-d7-royalmarsden-publicne-live.s3-eu-west-1.amazonaws.com/files_trust/s3fs-public/Clinical%20Genomics%20NHS%20Service%20Specification%20V1.2..pdf)Prior agreement essential.  |[ ]  [DNA NGS (RMH200)](https://shared-d7-royalmarsden-publicne-live.s3-eu-west-1.amazonaws.com/files_trust/s3fs-public/D.%20RMH%20NGS%20Panels_0.pdf) |[ ]   [RNA Fusions](https://emea.illumina.com/content/dam/illumina-marketing/documents/products/gene_lists/gene_list_trusight_pan_cancer.xlsx) | **FFPE block essential!****& Pathology report** |
| Test tbc |[ ]  Leave decision to molecular pathology team (for complex, unclear and other referrals) | **FFPE block****& Pathology report** |
| **Patient details** |
| First name |   | Sex  | M [ ]  | F [ ]  |
| Surname |   |
| Date of birth |  Click or tap to enter a date.  |
| **Hospital number** |   |
| **NHS Number** |   |
| Tumour location |   | Previous radiation [ ]  |
| Referred diagnosis |   |
| Referred material | **Block** [ ]  **4 slides (4µm) and 8-10 slides (10µm)** [ ]  |   |  |  |  |
| Referral Pathology ID and block number |   | Year of surgery |   |  | **4 slides (4µm) and 8-10 slides (10µm)** |  |  |
| **Details of the referring hospital and clinician or pathologist** |
| Hospital |   |
| Postcode |   |
| Requesting consultant |   |
|  |   |
| **Email address(es) for reports** |   |
| **Address to return material** |   |

Unlock password: npmolpath. Controlled document. Do not alter or edit.

Page 1 of 1. Stored as attachment in ipassport to NPATH-AD30-Proformas Authorised by SB